Investing.com - Mesoblast (NASDAQ:MESO) reported on Wednesday fourth quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Mesoblast announced earnings per share of $-0.2 on revenue of $11.89M. Analysts polled by Investing.com anticipated EPS of $-0.18 on revenue of $12.71M.
Mesoblast shares are up 148.71% from the beginning of the year, still down 13.62% from its 52 week high of $21.22 set on August 17. They are outperforming the Nasdaq which is up 30.01% from the start of the year.
Mesoblast follows other major Healthcare sector earnings this month
Mesoblast's report follows an earnings beat by Merck&Co on July 31, who reported EPS of $1.37 on revenue of $10.87B, compared to forecasts EPS of $1.06 on revenue of $10.4B.
AbbVie had beat expectations on July 31 with second quarter EPS of $2.34 on revenue of $10.43B, compared to forecast for EPS of $2.2 on revenue of $9.94B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar